Overview
The CYP2C9 gene accounts for nearly 20 percent of all cytochrome P450 enzyme volume in the human liver. It handles the oxidative breakdown of over-the-counter NSAID painkillers (ibuprofen, naproxen, diclofenac, celecoxib), the potent active enantiomer S-warfarin, antidiabetic sulfonylureas, anti-seizure drug phenytoin, and the multiple sclerosis therapy siponimod.
Roughly one-third of Europeans carry reduced-function *2 or *3 variants—making CYP2C9 one of the most frequent actionable targets in everyday medication safety.
10q23.33 (Chromosome 10)
Detoxification & Pharmacogenetics
Phase I Hepatic Drug Enzyme
NSAID, warfarin & phenytoin clearance
Function of CYP2C9
CPIC pharmacogenetic scoring assigns 1.0 to normal *1 alleles, 0.5 to *2, and ~0.0–0.25 to *3. Activity scores below 1.5 slow active-drug breakdown, prolonging blood residence time.
Key Aspects:
💊 Painkillers & Stomach Lining
Poor metabolizers (*3/*3 or *2/*3) accumulate high ibuprofen, meloxicam, or celecoxib blood levels over repeated days—elevating GI irritation, ulcer, and kidney risk.
🩸 Mandatory Pre-Treatment Check
Before prescribing siponimod (Mayzent), CYP2C9 genotyping is clinically mandatory: *3/*3 homozygotes are strictly contraindicated due to cardiac conduction risk.
🧬 Genetic Variants (SNPs)
Two coding SNPs identify the dominant European CYP2C9 *2 and *3 alleles:
10:94942290
Reduces cytochrome reductase interaction, lowering catalytic activity (~50% per allele) for warfarin and common NSAIDs.
~12% (Europe)
10:94981296
Distorts the substrate binding pocket, slashing clearance by up to ~85–90%; requires marked warfarin and phenytoin reductions.
~7% (Europe)
Practical Significance
✅ Strategies & Guidance
- Lowest Effective NSAID Dose: Poor metabolizers benefit from starting at 25–50% standard celecoxib/meloxicam/ibuprofen doses or using acetaminophen when appropriate.
- Pre-Warfarin / Siponimod Testing: Provide CYP2C9 status to prescribers prior to anticoagulation or MS therapy initiation.
- Monitor Blood Glucose on Sulfonylureas: Slow clearance of glipizide or glimepiride can trigger prolonged hypoglycemia.
⚠️ Clinical Notes & Risks
- GI & Renal NSAID Toxicity: Multi-day standard NSAID dosing in activity score 0–1 patients raises GI bleed risk.
- Supratherapeutic Warfarin INR: *2/*3 and *3/*3 genotypes reach dangerously thin blood faster on standard loading schedules.
- Phenytoin Ataxia: Accumulation produces dizziness, nystagmus, and slurred speech.
📚 Data Sources
- OMIM: #601130 (Cytochrome P450, Subfamily IIC, Polypeptide 9)
- dbSNP: rs1799853 (*2), rs1057910 (*3)
- CPIC Guidelines: CYP2C9 and NSAIDs, Warfarin, and Phenytoin
- PharmGKB: Clinical Annotations Level 1A for CYP2C9
Last Update: November 2026
Related Research Guides for CYP2C9
Related Genes in Detoxification
NAT2
NAT2 drives Phase II liver acetylation of drugs (isoniazid, sulfonamides) and heterocyclic amines. Variants divide individuals…
SLCO1B1
SLCO1B1 (OATP1B1) imports statin cholesterol drugs and bilirubin from blood into liver cells. The *5 variant…
SOD2
SOD2 protects mitochondria from oxidative damage by neutralizing superoxide radicals....